Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Avenue Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ATXI
Nasdaq
2834
http://www.avenuetx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Avenue Therapeutics Inc
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
- Mar 31st, 2022 11:30 am
FDA's AdComm Says Avenue Therapeutics Submitted Insufficient Data On IV Tramadol
- Feb 16th, 2022 1:20 pm
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol
- Feb 16th, 2022 3:00 am
Avenue Therapeutics Stock Trading Halted Today
- Feb 15th, 2022 12:05 pm
Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)
- Dec 15th, 2021 7:15 pm
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
- Dec 15th, 2021 5:00 pm
Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock
- Dec 13th, 2021 1:00 am
Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022
- Nov 29th, 2021 1:00 pm
Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option
- Nov 17th, 2021 2:30 pm
Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)
- Nov 12th, 2021 3:40 pm
Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock
- Nov 10th, 2021 2:30 am
Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs
- Oct 25th, 2021 11:00 am
Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study
- Aug 26th, 2021 3:04 pm
Monday’s Pre-Market: Here’s What You Need to Know Before the Market Opens
- Jun 21st, 2021 12:04 pm
CORRECTED-U.S. FDA declines to approve Avenue's painkiller again, shares drop
- Jun 14th, 2021 11:44 am
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
- Jun 14th, 2021 11:00 am
Scroll